Neoadjuvant epirubicin/docetaxel (ET) concomitant chemotherapy for primary breast cancer with tumor diameter >=3.1 cm: results of the Kyushu ET therapy phase II trial.
|
| Abstract | AIM: Neoadjuvant epirubicin/docetaxel (ET) combination chemotherapy was administered to breast cancer patients in order to investigate their clinical and pathological response. Moreover, the breast-conserving surgery (BCS) rate, disease-free (DFS) and overall survival (OS), safety profile and the correlation of biological markers were investigated. PATIENTS AND METHODS: Out of the 46 enrolled patients, 45 patients were analyzed for clinical response, and 40 patients were examined for pathological response. Estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor type2 (HER2) expression were examined immunohistologically. RESULTS: The median tumor size was 4.5 cm in diameter. Complete (CR) and partial responses were seen in 3 and 30 patients, respectively. A pathological CR was achieved in 4 patients and correlated with ER and PgR negativity. Moreover, BCS was performed on 16 patients. The 5-year cumulative DFS was 60.7% and OS was 91.8%. CONCLUSION: ET therapy is clinically effective with a pathological CR rate of 10% for patients with a large tumor, and should be considered as a neoadjuvant treatment option.
|
|---|---|
| Authors | Reiki Nishimura, Yoshiaki Rai, Fumie Matsuo, Keisei Anan, Shinsuke Hara, Shigeru Imamura, Noriaki Itoyanagi, Masato Kato, Masayuki Okido, Manabu Kudaka, Emi Ishikawa, Yoshihiko Kamada, Ryoji Watanabe, Mitsunori Shirouzu, Shoshu Mitsuyama, Yasushi Takamatsu, Kazuo Tamura |
| Journal | Anticancer research (Anticancer Res) Vol. 32 Issue 8 Pg. 3259-65 (Aug 2012) ISSN: 1791-7530 [Electronic] Greece |
| PMID | 22843900 (Publication Type: Clinical Trial, Phase II, Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!